Novo Nordisk A/S Class B (0QIU)
London Exchange · UK · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 259.13 |
|---|---|
| 52-week range | 224.55 – 409.90 |
| Return, 1 month / 3 months | +1.2% / −17.2% |
| Return, 1 year / 3 years | −20.8% / −59.0% |
| Trend | Below its 200-day average |
| RSI (14) | 46 |
| Volatility (1 year) | 47.8% |
| Worst drawdown (1 year) | -42.5% |
| Average daily value traded | 266.14M DKK |
| Dividend yield | 4.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novo Nordisk is a pharmaceutical company based in Denmark that develops and makes medicines for diabetes and other chronic conditions. Its products include insulin preparations and other injectable treatments for people with diabetes, along with therapies for growth disorders and bleeding disorders. It also supplies devices used to deliver these medicines. The company serves patients and healthcare professionals through sales in many countries, with its main operations rooted in Denmark.
The shares are listed on the London Exchange in UK under the code 0QIU, and the price on this page is in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novo Nordisk A/S Class B (0QIU) trades on the London Exchange in UK. It last closed at DKK 259.13 on 23 October 2026.
Its price-based Market X-Ray is 42 out of 100 (a weak price profile), ranking 2,506 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 20.8% and over the last three months it fell 17.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -8.8% | ||
| From 52-week high | -36.1% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.2% | ||
| 6-month return | 6.2% | ||
| 12-month return, skipping the last month | -21.8% | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 47.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -42.5% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 266.14M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −0.8% |
|---|---|
| 1 month | +1.2% |
| 3 months | −17.2% |
| 6 months | +6.2% |
| 1 year | −20.8% |
| 3 years | −59.0% |
| 5 years | −14.0% |
Signals
| 50-day / 200-day average | 274.00 / 284.19 |
|---|---|
| Golden / death cross (60 days) | Death, 13 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.58 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | DKK 3.7500 |
| 27 Mar 2026 | DKK 7.9500 |
| 15 Aug 2025 | DKK 3.7500 |
| 28 Mar 2025 | DKK 7.9000 |
| 15 Aug 2024 | DKK 3.5000 |
| 22 Mar 2024 | DKK 6.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.